Substituted saturated aza heterocycles as inhibitors of nitric o

Details Substituted saturated aza heterocycles as inhibitors of nitric o Substituted saturated aza heterocycles as inhibitors of nitric o

1996-11-08

1998-10-13

Shah, Mukund J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514408, 514315, 548570, 546246, 544242, C07D21106, A01N 4340

Patent

active

058212612

ABSTRACT:
Disclosed herein are compounds of Formula (I) ##STR1## and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These disease and disorders include hypotension, septic shock, toxic shock syndrom, hemodialysis, IL-2 therapy such as in cancer patients, cachexia, immnunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn or psoriasis and respiratory conditions such as bronchitis, asthma, and acure respiratory distress (ARDS), myocarditis, heart failure, atherosclerosis, arthritis, rheumatoid arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis. Compounds of Formula I are also useful in the treatment of hypoxia, hyperbaric oxygen convulsions and toxicity, dementia, Sydenham's chorea, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, Korsakoffs disease, imbecility related to cerebral vessel disorder, ischemic brain edema, sleeping disorders, schizophrenia, depression, PMS, anxiety, drug addiction, pain, migraine, immune complex disease, as immunosupressive agents and for preventing or reversing tolerance to opiates and diazepines.

REFERENCES:
patent: 5252586 (1993-10-01), Cain et al.
patent: 5489603 (1996-02-01), Uneme et al.
Webb et al. J. Org. Chem., vol. 56, No. 9, 1991, 3009-3016.
Nakane, et al., FEBS Letters, 316, 175-182 (1993).
Marsden, et al FEBS Letters, 307, 287-293 (1992).
Geller, et al, PNAS, 90, 34915 (1993).
Moncada, et al., Pharmacol, Reviews, 43, 109-142 (1991).
Nathan, FASEB J., 6, 3051-64 (1992).
Wright, et al., Card, Res., 26, 48-57 (1992).
Kilbourn, et al., PNAS, 87, 3628-32 (1990).
Beasley and Brunner, Kidney, Int., 42, Suppl., 38, S96-S100 (1992).
Hibbs, et al., J. Clin. Invest., 89, 867-77 (1992).
Miller, et al., J. Pharmacol. Exp. Ther., 264, 11-16 (1990).
Ialenti, et al., Br. J. Pharmacol., 110, 701-6 (1993).
Stevanovic-Racic, et al., Arth. & Rheum, 37, 1062-9 (1994).
Huang, et al., Science, 265, 1883-5 (1994).
J. Org. Chem., 1991, 56(9): 3010-3016.

Affiliated with

Also associated with

Rating

Substituted saturated aza heterocycles as inhibitors of nitric o does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted saturated aza heterocycles as inhibitors of nitric o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted saturated aza heterocycles as inhibitors of nitric o will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-313546